The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Niraparib plus PD-1 inhibitor for patients previously treated with immune checkpoint inhibitor for solid tumors with homologous recombination repair gene mutation (IMAGENE): A phase II basket study.
 
Taigo Kato
Honoraria - Bristol-Myers Squibb Japan; Merck; MSD; Pfizer; Takeda
Research Funding - Takeda
 
Takahiro Kojima
No Relationships to Disclose
 
Masaki Shiota
Honoraria - Astellas Pharma; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Janssen; Sanofi; Takeda
Research Funding - Astellas Pharma
 
Masashi Nakayama
Honoraria - Astellas Pharma; AstraZeneca Japan; Bayer Yakuhin; Bristol Myers Squibb; Chugai Pharma; Eisai; Janssen; Kissei Pharmaceutical; Merck; Merck; Ono Pharmaceutical; Sanofi; Takeda
 
Nobuaki Matsubara
Honoraria - Sanofi
Consulting or Advisory Role - Amgen; AstraZeneca; Janssen; Lilly; Pfizer; Sanofi; Seagen
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer Yakuhin (Inst); Chugai Pharma (Inst); Eisai (Inst); Janssen (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Roche/Genentech (Inst); Seagen (Inst); Takeda (Inst)
 
Kenjiro Namikawa
Honoraria - Bristol-Myers Squibb; MSD; Novartis; Ono Pharmaceutical
Consulting or Advisory Role - MSD; Novartis
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Novartis (Inst); Ono Pharmaceutical (Inst)
 
Takahiro Osawa
Honoraria - MSD; Ono Pharmaceutical; Takeda; Takeda; Takeda
 
Takashige Abe
No Relationships to Disclose
 
Yota Yasumizu
No Relationships to Disclose
 
Nobuyuki Tanaka
No Relationships to Disclose
 
Mototsugu Oya
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Ferring; Janssen; Merck; MSD; Novartis; Pfizer; Takeda
 
Nobuo Shinohara
Honoraria - Astellas Pharma; AstraZeneca; Janssen; MSD; Novartis; Ono Pharmaceutical; Pfizer; Takeda
Research Funding - Astellas Pharma (Inst); Ono Pharmaceutical (Inst)
 
Masatoshi Eto
Consulting or Advisory Role - Boston Scientific; Chugai Pharma; Eisai; Ferring; Intuitive Surgical; Merck; MSD; Novartis; Pfizer; Takeda
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Janssen; Merck; MSD; ONO PHARMACEUTICAL; Pfizer; Takeda
Research Funding - MSD
 
Takao Fujisawa
Honoraria - Amelief; AstraZeneca; Merck Serono
 
Susumu Okano
Speakers' Bureau - Bristol-Myers Squibb Japan; Meiji Seika Kaisha; Merck Serono; MSD; Ono Pharmaceutical
 
Eisuke Hida
Employment - Ono Pharmaceutical (I)
Consulting or Advisory Role - CureApp, Inc
Speakers' Bureau - Chugai Pharma
Research Funding - Shionogi
 
Yoshiaki Nakamura
Consulting or Advisory Role - DAIICHI SANKYO Co., Ltd.; Exact Sciences; Gilead Sciences; Guardant Health Pte Ltd; Natera,Inc.; Premo Partners, Inc.; Roche Ltd./; Seagen,Inc.; Takeda
Speakers' Bureau - Becton Dickinson; CareNet,Inc.; Chugai Pharma; DAIICHI SANKYO Co., Ltd.; Eisai; Guardant Health Japan Corp.; Guardant Health Pte Ltd; Hisamitsu Pharmaceutical; Merck; Miyarisan pharmaceutical; MSD K.K; Taiho Pharmaceutical; Zeria Pharmaceutical
Research Funding - Chugai Pharma (Inst); DAIICHI SANKYO Co., Ltd. (Inst); Genomedia (Inst); Guardant Health (Inst); Guardant Health AMEA, Inc. (Inst); Roche (Inst); Seagen,Inc. (Inst); Tempus (Inst)
 
Hideaki Bando
Honoraria - Chugai Pharma; Ono Pharmaceutical; Taiho Pharmaceutical
 
Takayuki Yoshino
Honoraria - Chugai Pharma; Merck; MSD K.K.; Takeda
Consulting or Advisory Role - Sumitomo Corp.
Research Funding - Amgen (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); Eisai (Inst); FALCO biosystems Ltd. (Inst); Medical & Biological Laboratories Co., Ltd. (Inst); Merus (Inst); Molecular Health (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Norio Nonomura
Honoraria - Astellas Pharma; AstraZeneca; Asuka Seiyaku; Bayer; Bristol-Myers Squibb; Chugai Pharma; Eisai; Janssen; Kissei Pharmaceutical; Kyorin; MSD; Nippon Shinyaku; Ono Pharmaceutical; Pfizer; Takeda
Research Funding - Nippon Shinyaku (Inst)